|
CA2749325C
(en)
*
|
2009-02-02 |
2021-03-30 |
Okairos Ag |
Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
|
|
PH12012500908A1
(en)
|
2009-11-09 |
2017-08-23 |
Genvec Inc |
Methods of propagating monkey adenoviral vectors
|
|
WO2011130627A2
(en)
|
2010-04-16 |
2011-10-20 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Chimpanzee adenoviral vector-based filovirus vaccines
|
|
AU2011332025B2
(en)
*
|
2010-11-23 |
2015-06-25 |
The Trustees Of The University Of Pennsylvania |
Subfamily E simian adenoviruses A1321, A1325, A1295, A1309 and A1322 and uses thereof
|
|
WO2012089231A1
(en)
|
2010-12-30 |
2012-07-05 |
Okairòs Ag |
Paramyxovirus vaccines
|
|
TWI623618B
(zh)
|
2011-07-12 |
2018-05-11 |
傳斯堅公司 |
Ｈｂｖ聚合酶突變體
|
|
WO2013045668A2
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
WO2013045658A1
(en)
|
2011-09-29 |
2013-04-04 |
Transgene Sa |
Immunotherapy composition and regimen for treating hepatitis c virus infection
|
|
EP2764014B1
(en)
|
2011-10-05 |
2022-02-09 |
GenVec, Inc. |
Adenoviral vectors and methods of use
|
|
CN107937440A
(zh)
|
2011-10-05 |
2018-04-20 |
金维克有限公司 |
猴腺病毒(大猩猩)或腺病毒载体及其使用方法
|
|
BR112014008167B1
(pt)
*
|
2011-10-05 |
2022-05-24 |
Genvec Inc |
Adenovírus ou vetor adenoviral e composição os compreendendo
|
|
US20130122038A1
(en)
|
2011-11-14 |
2013-05-16 |
The United States Of America As Represented By The Secretary Of The Department |
Heterologous prime-boost immunization using measles virus-based vaccines
|
|
US8932607B2
(en)
|
2012-03-12 |
2015-01-13 |
Crucell Holland B.V. |
Batches of recombinant adenovirus with altered terminal ends
|
|
SI2825640T1
(sl)
|
2012-03-12 |
2016-08-31 |
Crucell Holland B.V. |
Šarže rekombinantnega adenovirusa s spremenjenimi konci
|
|
RU2737765C2
(ru)
|
2012-05-04 |
2020-12-02 |
Пфайзер Инк. |
Простатоассоциированные антигены и иммунотерапевтические схемы на основе вакцин
|
|
SG10201609511XA
(en)
*
|
2012-05-18 |
2016-12-29 |
Univ Pennsylvania |
Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
|
|
WO2013180967A1
(en)
|
2012-05-29 |
2013-12-05 |
Genvec, Inc. |
Herpes simplex virus vaccine
|
|
SI2869841T1
(sl)
|
2012-07-05 |
2022-02-28 |
Glaxosmithkline Biologicals Sa |
Novi režimi za ojačitev odziva, ki vključujejo imunogene polipeptide, ki jih kodirajo polinukleotidi
|
|
WO2014005643A1
(en)
*
|
2012-07-05 |
2014-01-09 |
Okairos Ag |
Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides
|
|
ES3040856T3
(en)
|
2012-11-16 |
2025-11-05 |
Beth Israel Deaconess Medical Ct Inc |
Recombinant adenoviruses and use thereof
|
|
SG11201507393TA
(en)
|
2013-03-14 |
2015-10-29 |
Salk Inst For Biological Studi |
Oncolytic adenovirus compositions
|
|
WO2014139587A1
(en)
|
2013-03-15 |
2014-09-18 |
Okairòs Ag |
Improved poxviral vaccines
|
|
AU2014259474B2
(en)
|
2013-04-25 |
2018-09-13 |
Janssen Vaccines & Prevention B.V. |
Stabilized soluble prefusion RSV F polypeptides
|
|
WO2015092710A1
(en)
|
2013-12-19 |
2015-06-25 |
Glaxosmithkline Biologicals, S.A. |
Contralateral co-administration of vaccines
|
|
US11571472B2
(en)
|
2014-06-13 |
2023-02-07 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
|
FI3656395T3
(fi)
|
2014-09-03 |
2024-02-05 |
Bavarian Nordic As |
Menetelmiä ja koostumuksia suojaavan immuniteetin aikaansaamiseksi filovirusinfektiota vastaan
|
|
JP2017527564A
(ja)
|
2014-09-03 |
2017-09-21 |
バヴァリアン ノルディック エー／エス |
免疫応答の増進を目的とする方法及び組成物
|
|
WO2017025782A1
(en)
|
2014-09-17 |
2017-02-16 |
Glaxosmithkline Biologicals Sa |
Improved poxviral vaccines
|
|
PL3198009T3
(pl)
|
2014-09-24 |
2022-01-24 |
Salk Institute For Biological Studies |
Onkolityczne wirusy nowotworowe i sposoby zastosowania
|
|
HUE053585T2
(hu)
|
2014-09-26 |
2021-07-28 |
Beth Israel Deaconess Medical Ct Inc |
Eljárások és készítmények humán immundeficiencia vírus fertõzés elleni védõ immunválasz indukálására
|
|
ES3011733T3
(en)
|
2015-02-13 |
2025-04-08 |
Transgene |
Immunotherapeutic vaccine and antibody combination therapy
|
|
WO2016131945A1
(en)
|
2015-02-20 |
2016-08-25 |
Transgene Sa |
Combination product with autophagy modulator
|
|
CA2981841A1
(en)
|
2015-04-14 |
2016-10-20 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenovirus expressing two transgenes with a bidirectional promoter
|
|
JP6893177B2
(ja)
|
2015-05-15 |
2021-06-23 |
キュアバック アーゲー |
少なくとも１つのｍＲＮＡコンストラクトの投与を含むプライムブーストレジメン（ＰＲＩＭＥ−ＢＯＯＳＴ ＲＥＧＩＭＥＮＳ）
|
|
BE1024824B1
(fr)
*
|
2015-06-12 |
2018-07-13 |
Glaxosmithkline Biologicals Sa |
Polynucleotides et polypeptides d'adenovirus
|
|
GB201514772D0
(en)
*
|
2015-08-19 |
2015-09-30 |
Glaxosmithkline Biolog Sa |
Adenovirus polynucleotides and polypeptides
|
|
KR102535670B1
(ko)
*
|
2015-06-12 |
2023-05-22 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
아데노바이러스 폴리뉴클레오티드 및 폴리펩티드
|
|
CA2991002C
(en)
|
2015-07-07 |
2023-11-28 |
Janssen Vaccines & Prevention B.V. |
Vaccine against rsv
|
|
JP6840718B2
(ja)
|
2015-07-07 |
2021-03-10 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
安定化された可溶性融合前ｒｓｖ ｆポリペプチド
|
|
GB201513176D0
(en)
*
|
2015-07-27 |
2015-09-09 |
Glaxosmithkline Biolog Sa |
Novel methods for inducing an immune response
|
|
PL3390430T3
(pl)
|
2015-12-15 |
2020-03-31 |
Janssen Vaccines & Prevention B.V. |
Antygeny ludzkiego wirusa niedoboru odporności, wektory, kompozycje i sposoby ich zastosowania
|
|
ES2811523T3
(es)
|
2016-01-19 |
2021-03-12 |
Pfizer |
Vacunas contra el cáncer
|
|
JP7015551B2
(ja)
|
2016-02-23 |
2022-02-15 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
ウイルス動態への影響を最小限にするための治療用アデノウイルスにおける外因性遺伝子発現
|
|
JP7054527B2
(ja)
|
2016-02-23 |
2022-04-14 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
アデノウイルスの複製動態を測定するための高スループットアッセイ
|
|
HUE072880T2
(hu)
|
2016-03-31 |
2025-12-28 |
The European Molecular Biology Laboratory |
Adenovírus szálfehérjékbõl származó módosított polipeptidek és a polipeptideket tartalmazó VLP-k
|
|
PT3439672T
(pt)
|
2016-04-05 |
2021-02-24 |
Janssen Vaccines & Prevention Bv |
Proteína f do rsv pré-fusão solúvel e estabilizada para uso na profilaxia de infeção por rsv
|
|
KR102500970B1
(ko)
|
2016-04-05 |
2023-02-17 |
얀센 백신스 앤드 프리벤션 비.브이. |
Rsv에 대한 백신
|
|
EP3452081A1
(en)
|
2016-05-04 |
2019-03-13 |
Transgene SA |
Combination therapy with cpg tlr9 ligand
|
|
JP7046835B2
(ja)
|
2016-05-12 |
2022-04-04 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
強力でバランスのとれた双方向性プロモーター
|
|
KR102421049B1
(ko)
|
2016-05-30 |
2022-07-15 |
얀센 백신스 앤드 프리벤션 비.브이. |
안정화된 융합-전 rsv f 단백질
|
|
CN109312362B
(zh)
|
2016-06-20 |
2022-06-28 |
扬森疫苗与预防公司 |
有效和平衡的双向启动子
|
|
GB2549809C
(en)
*
|
2016-06-23 |
2022-11-30 |
Univ Oxford Innovation Ltd |
Vector
|
|
WO2018011198A1
(en)
|
2016-07-15 |
2018-01-18 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
WO2018011768A1
(en)
|
2016-07-15 |
2018-01-18 |
Janssen Vaccines And Prevention B.V. |
Methods and compositions for inducing protective immunity against a marburg virus infection
|
|
EP3504230A1
(en)
*
|
2016-08-23 |
2019-07-03 |
GlaxoSmithKline Biologicals SA |
Fusion peptides with antigens linked to short fragments of invariant chain (cd74)
|
|
EP3518966A1
(en)
|
2016-09-29 |
2019-08-07 |
GlaxoSmithKline Biologicals S.A. |
Compositions and methods of treatment of persistent hpv infection
|
|
GB201616904D0
(en)
|
2016-10-05 |
2016-11-16 |
Glaxosmithkline Biologicals Sa |
Vaccine
|
|
EP3522920A2
(en)
|
2016-10-10 |
2019-08-14 |
Transgene SA |
Immunotherapeutic product and mdsc modulator combination therapy
|
|
GB201620968D0
(en)
|
2016-12-09 |
2017-01-25 |
Glaxosmithkline Biologicals Sa |
Adenovirus polynucleotides and polypeptides
|
|
CN110036020A
(zh)
*
|
2016-12-09 |
2019-07-19 |
葛兰素史密丝克莱恩生物有限公司 |
具有狂犬病病毒抗原的黑猩猩腺病毒构建体
|
|
WO2018111767A1
(en)
|
2016-12-12 |
2018-06-21 |
Salk Institute For Biological Studies |
Tumor-targeting synthetic adenoviruses and uses thereof
|
|
GB201701239D0
(en)
*
|
2017-01-25 |
2017-03-08 |
Glaxosmithkline Biologicals Sa |
Novel formulation
|
|
SG11201906271QA
(en)
|
2017-02-09 |
2019-08-27 |
Janssen Vaccines & Prevention Bv |
Potent and short promoter for expression of heterologous genes
|
|
US11173204B2
(en)
|
2017-04-06 |
2021-11-16 |
Janssen Vaccines & Prevention B.V. |
MVA-BN and Ad26.ZEBOV or Ad26.filo prime-boost regimen
|
|
TW201907937A
(zh)
|
2017-05-08 |
2019-03-01 |
美商葛利史東腫瘤科技公司 |
阿爾法病毒新抗原載體
|
|
US20210189432A1
(en)
*
|
2017-05-10 |
2021-06-24 |
University Of Utah Research Foundation |
Compositions and methods of use of arc capsids
|
|
JP2020519663A
(ja)
|
2017-05-17 |
2020-07-02 |
ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． |
Ｒｓｖ感染に対する防御免疫を誘導するための方法及び組成物
|
|
WO2018210871A1
(en)
|
2017-05-17 |
2018-11-22 |
Janssen Vaccines & Prevention B.V. |
Methods and compositions for inducing protective immunity against rsv infection
|
|
BR112019026126A2
(pt)
|
2017-06-15 |
2020-06-30 |
Janssen Vaccines & Prevention B.V. |
vetores de poxvírus que codificam antígenos do hiv e métodos de uso dos mesmos
|
|
SG11201913178WA
(en)
*
|
2017-07-05 |
2020-01-30 |
Nouscom Ag |
Non human great apes adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
|
|
CN111065408A
(zh)
|
2017-07-11 |
2020-04-24 |
辉瑞公司 |
免疫原性组合物
|
|
BR112020000581A2
(pt)
|
2017-07-12 |
2020-07-14 |
Nouscom Ag |
polipeptídeo, ácido nucleico, vetor, coleção de um ou mais vetores de expressão, composição compreendendo uma vacina e kit de vacinação
|
|
EP3655539A1
(en)
|
2017-07-21 |
2020-05-27 |
GlaxoSmithKline Biologicals S.A. |
Chikungunya virus antigen constructs
|
|
WO2019023566A1
(en)
|
2017-07-28 |
2019-01-31 |
Janssen Vaccines & Prevention B.V. |
METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP
|
|
US11229695B2
(en)
|
2017-09-15 |
2022-01-25 |
Janssen Vaccines & Prevention B.V. |
Method for the safe induction of immunity against RSV
|
|
CA3079048A1
(en)
|
2017-10-16 |
2019-04-25 |
Glaxosmithkline Biologicals Sa |
Adenoviral vectors with two expression cassettes encoding rsv antigenic proteins or fragments thereof
|
|
KR20200066349A
(ko)
|
2017-10-16 |
2020-06-09 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
복제 가능 아데노바이러스 벡터
|
|
CA3084346A1
(en)
|
2017-10-16 |
2019-04-25 |
Glaxosmithkline Biologicals Sa |
Simian adenoviral vectors with two expression cassettes
|
|
EP3697902A1
(en)
|
2017-10-16 |
2020-08-26 |
GlaxoSmithKline Biologicals S.A. |
Enhanced promoter
|
|
EP3704256A1
(en)
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus vectors and uses thereof
|
|
EP3704139A1
(en)
*
|
2017-10-31 |
2020-09-09 |
Janssen Vaccines & Prevention B.V. |
Adenovirus and uses thereof
|
|
SG11202003200VA
(en)
|
2017-10-31 |
2020-05-28 |
Janssen Vaccines & Prevention Bv |
Adenovirus and uses thereof
|
|
JP7366014B2
(ja)
|
2017-10-31 |
2023-10-20 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルス及びその用途
|
|
EP3703744A1
(en)
|
2017-11-03 |
2020-09-09 |
Nouscom AG |
Vaccine t cell enhancer
|
|
BR112020007884A2
(pt)
|
2017-11-20 |
2020-11-03 |
Janssen Pharmaceuticals, Inc. |
método de proporcionar uma administração segura de vetores adenovirais que codificam um antígeno de vírus zika
|
|
EP3723771A4
(en)
|
2017-12-11 |
2022-04-06 |
Beth Israel Deaconess Medical Center, Inc. |
Recombinant adenoviruses and uses thereof
|
|
GB201721069D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B Immunisation regimen and compositions
|
|
GB201721068D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Biologicals Sa |
Hepatitis B immunisation regimen and compositions
|
|
MX2020006471A
(es)
|
2017-12-19 |
2020-09-22 |
Janssen Sciences Ireland Unlimited Co |
Metodos y composiciones para inducir una respuesta inmune contra el virus de hepatitis b (hbv).
|
|
MX2020006225A
(es)
|
2017-12-20 |
2020-12-07 |
Glaxosmithkline Biologicals Sa |
Constructos antigenicos del virus de epstein-barr.
|
|
JP7430395B2
(ja)
|
2018-04-09 |
2024-02-13 |
ソーク インスティテュート フォー バイオロジカル スタディーズ |
複製特質が増強された腫瘍溶解性アデノウイルス組成物
|
|
CN112638936A
(zh)
|
2018-06-12 |
2021-04-09 |
葛兰素史密丝克莱恩生物有限公司 |
腺病毒多核苷酸和多肽
|
|
EP3581201A1
(en)
|
2018-06-15 |
2019-12-18 |
GlaxoSmithKline Biologicals S.A. |
Escherichia coli o157:h7 proteins and uses thereof
|
|
EP3587581A1
(en)
|
2018-06-26 |
2020-01-01 |
GlaxoSmithKline Biologicals S.A. |
Formulations for simian adenoviral vectors having enhanced storage stability
|
|
US11713469B2
(en)
|
2018-07-20 |
2023-08-01 |
Janssen Vaccines & Prevention B.V. |
Recombinant adenoviral vector expressing Zika antigen with improved productivity
|
|
GB201812647D0
(en)
*
|
2018-08-03 |
2018-09-19 |
Chancellor Masters And Scholars Of The Univ Of Oxford |
Viral vectors and methods for the prevention or treatment of cancer
|
|
BR112021003499A2
(pt)
*
|
2018-10-19 |
2021-05-18 |
Nouscom Ag |
polipeptídeo, polinucleotídeo, vetor, coleção de dois ou mais vetores, composição farmacêutica e kit
|
|
CN113164583A
(zh)
|
2018-11-13 |
2021-07-23 |
扬森疫苗与预防公司 |
稳定的融合前rsv f蛋白
|
|
JP7477888B2
(ja)
|
2018-11-15 |
2024-05-02 |
ノイスコム アーゲー |
個別化された癌ワクチンの作製のための癌変異の選択
|
|
TWI852977B
(zh)
|
2019-01-10 |
2024-08-21 |
美商健生生物科技公司 |
前列腺新抗原及其用途
|
|
CN113573730A
(zh)
|
2019-03-05 |
2021-10-29 |
葛兰素史密斯克莱生物公司 |
乙型肝炎免疫方案和组合物
|
|
JP7406263B2
(ja)
*
|
2019-03-20 |
2023-12-27 |
国立大学法人北海道大学 |
改変アデノウイルス及びこれを含む医薬
|
|
MX2021014525A
(es)
*
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
JP7711050B2
(ja)
*
|
2019-10-03 |
2025-07-22 |
ヤンセン ファッシンズ アンド プリベンション ベーフェー |
アデノウイルスベクターおよびその使用
|
|
EP4125973A4
(en)
*
|
2019-11-04 |
2024-03-13 |
Gritstone bio, Inc. |
NEOANTIGEN VACCINE THERAPY
|
|
CN114980920A
(zh)
|
2019-11-18 |
2022-08-30 |
詹森生物科技公司 |
基于突变体calr和jak2的疫苗及其用途
|
|
CN113088530A
(zh)
*
|
2020-01-08 |
2021-07-09 |
怡道生物科技(苏州)有限公司 |
一种基于黑猩猩ChAd63型腺病毒的表达载体及其构建方法
|
|
WO2021155323A1
(en)
|
2020-01-31 |
2021-08-05 |
Beth Israel Deaconess Medical Center, Inc. |
Compositions and methods for preventing and treating coronavirus infection-sars-cov-2 vaccines
|
|
TW202144389A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在多發性骨髓瘤中表現之新抗原及其用途
|
|
TW202144388A
(zh)
|
2020-02-14 |
2021-12-01 |
美商健生生物科技公司 |
在卵巢癌中表現之新抗原及其用途
|
|
EP4135757A1
(en)
|
2020-04-13 |
2023-02-22 |
Janssen Biotech, Inc. |
Psma and steap1 vaccines and their uses
|
|
AU2021269783A1
(en)
|
2020-05-11 |
2022-12-08 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
WO2022002894A1
(en)
|
2020-06-29 |
2022-01-06 |
Janssen Vaccines & Prevention B.V. |
Vaccine combination against respiratory syncytial virus infection
|
|
KR20230035340A
(ko)
|
2020-07-06 |
2023-03-13 |
얀센 파마슈티칼즈, 인코포레이티드 |
안정화된 코로나 바이러스 스파이크 단백질 융합 단백질
|
|
WO2022009052A2
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
Prostate neoantigens and their uses
|
|
US20250066740A1
(en)
*
|
2020-07-06 |
2025-02-27 |
Jiaxing Anyu Biotechnology Co., Ltd |
Novel chimpanzee adenovirus vector, construction method therefor, and application thereof
|
|
WO2022009051A1
(en)
|
2020-07-06 |
2022-01-13 |
Janssen Biotech, Inc. |
A method for determining responsiveness to prostate cancer treatment
|
|
US20230024133A1
(en)
|
2020-07-06 |
2023-01-26 |
Janssen Biotech, Inc. |
Prostate Neoantigens And Their Uses
|
|
CA3188801A1
(en)
|
2020-07-08 |
2022-01-13 |
Janssen Sciences Ireland Unlimited Company |
Rna replicon vaccines against hbv
|
|
CN116322740A
(zh)
|
2020-07-13 |
2023-06-23 |
特兰斯吉恩股份有限公司 |
免疫抑制的治疗
|
|
EP4192496A4
(en)
*
|
2020-08-06 |
2025-01-01 |
Gritstone bio, Inc. |
MULTIEPITOP VACCINE CASSETTES
|
|
US12275766B2
(en)
|
2020-12-23 |
2025-04-15 |
Janssen Biotech, Inc. |
Neoantigen peptide mimics
|
|
EP4294436A1
(en)
|
2021-02-19 |
2023-12-27 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion rsv fb fantigens
|
|
WO2022175479A1
(en)
|
2021-02-19 |
2022-08-25 |
Janssen Vaccines & Prevention B.V. |
Vaccine combinations against respiratory syncytial virus strain a and b infections
|
|
EP4314019A2
(en)
|
2021-04-01 |
2024-02-07 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion piv3 f proteins
|
|
WO2022218997A1
(en)
|
2021-04-12 |
2022-10-20 |
Centre National De La Recherche Scientifique (Cnrs) |
Novel universal vaccine presenting system
|
|
AU2022299252A1
(en)
|
2021-06-21 |
2023-11-23 |
Nouscom Ag |
Vaccine composition comprising encoded adjuvant
|
|
WO2023020939A1
(en)
|
2021-08-17 |
2023-02-23 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023026182A1
(en)
|
2021-08-24 |
2023-03-02 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
WO2023047348A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized corona virus spike protein fusion proteins
|
|
WO2023047349A1
(en)
|
2021-09-24 |
2023-03-30 |
Janssen Pharmaceuticals, Inc. |
Stabilized coronavirus spike protein fusion proteins
|
|
WO2023111725A1
(en)
|
2021-12-14 |
2023-06-22 |
Janssen Pharmaceuticals, Inc. |
Sars-cov-2 vaccines
|
|
EP4448802A1
(en)
|
2021-12-16 |
2024-10-23 |
Janssen Vaccines & Prevention B.V. |
Stabilized pre-fusion hmpv fusion proteins
|
|
WO2023198815A1
(en)
|
2022-04-14 |
2023-10-19 |
Janssen Vaccines & Prevention B.V. |
Sequential administration of adenoviruses
|
|
WO2023213764A1
(en)
|
2022-05-02 |
2023-11-09 |
Transgene |
Fusion polypeptide comprising an anti-pd-l1 sdab and a member of the tnfsf
|
|
WO2024061759A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Stabilized coronavirus s proteins
|
|
WO2024061757A1
(en)
|
2022-09-23 |
2024-03-28 |
Janssen Vaccines & Prevention B.V. |
Pre-fusion human piv1 f proteins
|
|
CN120344553A
(zh)
|
2022-10-06 |
2025-07-18 |
Msd国际商务股份有限公司 |
稳定的融合前piv3 f蛋白
|
|
WO2025158316A1
(en)
|
2024-01-26 |
2025-07-31 |
Janssen Biotech, Inc. |
Ovarian neoantigens and use thereof
|